[Comment] Dolutegravir in neonates: finally we are getting there!

Dolutegravir, a potent second-generation integrase strand inhibitor (INSTI), is the backbone of HIV treatment regimens for most children aged 1 month or older, adolescents, and adults with HIV globally. Neonates (aged 28 days or younger) have been the last to benefit, receiving more toxic and less efficacious antiretroviral medications for both prophylaxis and treatment regimens. The paucity of safety and pharmacokinetic studies in this age group has been a major hurdle to accessing optimised therapeutic options.